Efficacy and safety of apremilast in a patient with paraneoplastic dermatomyositis with resistant skin disease

Clin Exp Rheumatol. 2023 Mar;41(2):396-397. doi: 10.55563/clinexprheumatol/e3gjax. Epub 2023 Mar 2.

Authors

Nicola Cabas¹, Marco Turina², Stefano Pizzolitto², Salvatore De Vita¹, Luca Quartuccio³

Affiliations

¹ Division of Rheumatology, Department of Medicine, University of Udine, ASUFC, Udine, Italy.
² Unit of Pathology, Santa Maria della Misericordia Academic Medical Centre, Udine, Italy.
³ Division of Rheumatology, Department of Medicine, University of Udine, ASUFC, Udine, Italy. luca.quartuccio@uniud.it.

PMID: 36861740
DOI: 10.55563/clinexprheumatol/e3gjax

No abstract available

Publication types

Letter

MeSH terms

Dermatomyositis* / complications
Dermatomyositis* / diagnosis
Dermatomyositis* / drug therapy
Humans
Patients
Thalidomide / adverse effects

Substances

apremilast
Thalidomide